Ardian Sells Majority Stake in Unither Pharmaceuticals to GIC and IK Partners’ Lead Investor Group
Posted on 10/26/2022
Unither Pharmaceuticals was spun out of Sanofi in 1993. Unither is a European pharmaceutical contract development and manufacturing organization (CDMO) producing complex sterile liquid formulations for medical use and is currently the global market leader in the Blow-Fill-Seal (BFS) technology, a sterile single-unit dosage format. Headquartered in Amiens, France, Unither employs more than 1,600 people across seven manufacturing facilities in France, the U.S., Brazil, and China, as well as an additional R&D center in Bordeaux, France. Its products are sold in over 100 countries demonstrating a well-established global footprint.
An investor group led by IK Partners and Singapore’s GIC Private Limited are investing in Unither, alongside Keensight Capital and Parquest, reinforcing their existing positions. Ardian announced the sale of its majority stake in Unither. The Unither management team, including Eric Goupil, CEO of Unither, also increased their ownership in the company. Completion of the transaction is subject to relevant legal and regulatory approvals.
